Nutra Pharma Corp (NPHC)

[fly_fisherman]

Orphan Drug Status - Pediatric MS(RPI-78M)


Look at the other possible neurological disorders this may serve!!

FDA TRIALS PHASE II Soon!!!

http://www.receptopharm.com/drug_development/

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).


RPI-MN and RPI-78M possess several desirable properties as drugs:

They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.

They display no serious adverse side effects following years of investigations in humans and animals.

They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.

They are easy to administer.

RPI-78M can be administered orally a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.

RPI-78M
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration
https://finance.yahoo.com/news/nutra-pharmas-rpi-78m-granted-123000069.html

RPI-78M
Collaboration: University of Maryland,production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis
https://finance.yahoo.com/news/nutra-pharma-announces-collaboration-university-123000318.html


Interesting Older Post on Market Cap Related to the Orphan Drug Status and FDA Trials......


I believe with the toxic's everything had been slowed down to a crawl. I also believe things are soon to pick up steam.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133351752

30 million Market Cap: PPS .015
100 million Market Cap: PPS .05

Those numbers were based primarily on the Orphan Drug Status - Pediatric MS going to Phase II FDA trials!